Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeting T cells for GVHD therapy

D A Vallera1

  • 1Department of Therapeutic Radiology-Radiation Oncology, University of Minnesota, Minneapolis 55455, USA.

Seminars in Cancer Biology
|April 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Heterodimeric Bispecific Single Chain Variable Fragments (scFv) Killer Engagers (BiKEs) Enhance NK-cell Activity Against CD133+ Colorectal Cancer Cells.

Targeted oncology·2015
Same author

Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity.

British journal of cancer·2009
Same author

Genetically designing a more potent antipancreatic cancer agent by simultaneously co-targeting human IL13 and EGF receptors in a mouse xenograft model.

Gut·2008
Same author

In vitro efficacy of recombinant diphtheria toxin-murine interleukin-4 immunoconjugate on mouse glioblastoma and neuroblastoma cell lines and the additive effect of radiation.

Neurosurgical focus·2006
Same author

Preclinical studies targeting normal and leukemic hematopoietic cells with Yttrium-90-labeled anti-CD45 antibody in vitro and in vivo in nude mice.

Cancer biotherapy & radiopharmaceuticals·2003
Same author

Chimeric fusion proteins--diphtheria toxin-based.

Current opinion in investigational drugs (London, England : 2000)·2001

Immunotoxins show promise for controlling graft-versus-host disease (GVHD) after bone marrow transplantation. This approach could expand the use of transplantation for life-threatening diseases by reducing GVHD risks.

Area of Science:

  • Immunology
  • Hematology
  • Oncology

Background:

  • Bone marrow transplantation is a vital treatment for life-threatening diseases.
  • Graft-versus-host disease (GVHD) is a significant complication limiting transplant applications.
  • Current treatments for GVHD are often insufficient, especially for drug-refractory cases.

Purpose of the Study:

  • To discuss the development of immunotoxin strategies for GVHD.
  • To explore the potential of immunotoxins in preventing or treating GVHD.
  • To examine the limitations associated with immunotoxin therapies for GVHD.

Main Methods:

  • Review of immunotoxin development for GVHD control.
  • Analysis of immunotoxin efficacy in preclinical and clinical settings.

Related Experiment Videos

  • Discussion of challenges and future directions for immunotoxin application.

    • Main Results:

    • Immunotoxins represent a potential therapeutic avenue for managing GVHD.
    • Targeted elimination of alloreactive lymphocytes using immunotoxins may mitigate GVHD.
    • Further research is needed to optimize immunotoxin delivery and specificity.

    Conclusions:

    • Immunotoxins offer a promising strategy to reduce the risks associated with bone marrow transplantation.
    • Controlling GVHD with immunotoxins could broaden the therapeutic scope of bone marrow transplantation.
    • Addressing the limitations of immunotoxins is crucial for their successful clinical implementation.